Literature DB >> 17194711

Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent.

Michael Maeng1, Lisette Okkels Jensen, Klaus Rasmussen, Jens Flensted Lassen, Lars Romer Krusell, Per Thayssen, Leif Thuesen.   

Abstract

OBJECTIVE: To identify risk factors for clinical-driven target lesion revascularisation (TLR) in patients treated with sirolimus-eluting (Cypher) or paclitaxel-eluting (Taxus) stents in a real-world scenario.
DESIGN: From 1 January 2003 to 18 May 2005, all patients treated with a Cypher or Taxus stent were consecutively registered and followed for 9 months. Re-intervention was driven by clinical symptoms.
SETTING: Western Denmark Heart Registry. PATIENTS: 4432 patients with 6102 lesions treated with a Cypher (n = 3791 lesions) or Taxus (n = 2311 lesions) stent.
INTERVENTIONS: Percutaneous coronary intervention. MAIN OUTCOME MEASURES: TLR, defined as either new percutaneous coronary intervention or coronary artery bypass graft operation of the target lesion, within 9 months from the index procedure.
RESULTS: TLR within 9 months was performed in 2.5% of lesions treated with the Cypher stent and in 3.3% of lesions treated with the Taxus stent (OR 1.36, 95% CI 1.00 to 1.84). After adjustment by multivariate logistic regression, Taxus stent implantation was an independent predictor of TLR (OR 1.43, 95% CI 1.05 to 1.95). Implantation of >1 stent per lesion (OR 1.62, 95% CI 1.13 to 2.33) and reference diameter <2.8 mm (OR 1.42, 95% CI 1.00 to 2.02) were also identified as independent predictors of TLR.
CONCLUSIONS: These data from the registry reflect a real-world clinical scenario with operator-driven use of drug-eluting stents and symptom-driven re-intervention. In this setting, use of the Taxus stent, implantation of multiple stents per lesion and stent implantation in small vessels were independent predictors of TLR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194711      PMCID: PMC1955176          DOI: 10.1136/hrt.2006.100594

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial.

Authors:  Jean-Jacques Goy; Jean-Christophe Stauffer; Manon Siegenthaler; Alain Benoît; Charles Seydoux
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

3.  The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.

Authors:  Andrew T L Ong; Patrick W Serruys; Jiro Aoki; Angela Hoye; Carlos A G van Mieghem; Gaston A Rodriguez-Granillo; Marco Valgimigli; Karel Sonnenschein; Evelyn Regar; Martin van der Ent; Peter P T de Jaegere; Eugene P McFadden; Georgios Sianos; Willem J van der Giessen; Pim J de Feyter; Ron T van Domburg
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

4.  Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators.

Authors:  P N Ruygrok; R Melkert; M A Morel; J A Ormiston; F W Bär; F Fernandez-Avilès; H Suryapranata; K D Dawkins; C Hanet; P W Serruys
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

5.  Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes.

Authors:  S J Hong; M H Kim; T H Ahn; Y K Ahn; J H Bae; W J Shim; Y M Ro; D-S Lim
Journal:  Heart       Date:  2006-01-31       Impact factor: 5.994

6.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Nicolas von Beckerath; Alban Dibra; Jörg Hausleiter; Jürgen Pache; Helmut Schühlen; Claus Schmitt; Josef Dirschinger; Albert Schömig
Journal:  JAMA       Date:  2005-01-12       Impact factor: 56.272

7.  Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.

Authors:  Adnan Kastrati; Alban Dibra; Sonja Eberle; Julinda Mehilli; José Suárez de Lezo; Jean-Jacque Goy; Kurt Ulm; Albert Schömig
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  1 in total

1.  Existing data sources for clinical epidemiology: The Western Denmark Heart Registry.

Authors:  Morten Schmidt; Michael Maeng; Carl-Johan Jakobsen; Morten Madsen; Leif Thuesen; Per Hostrup Nielsen; Hans Erik Bøtker; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.